{"id":111107,"date":"2026-06-10T09:58:42","date_gmt":"2026-06-10T04:28:42","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=111107"},"modified":"2026-06-10T09:58:44","modified_gmt":"2026-06-10T04:28:44","slug":"bliss-gvs-pharma-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/","title":{"rendered":"Bliss GVS Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The Bliss GVS Pharma share price target 2026 is Rs 510, implying approximately 20 percent upside from the current market price of Rs 424.05 (NSE: BLISSGVS). Q4 FY26 results announced May 30, 2026 are the key near-term trigger, with Pharmaceutical Formulations and Export tailwinds and RBI rate cuts supporting re-rating toward Rs 510.<\/em><\/p>\n<p>The <strong><a href=\"https:\/\/univest.in\/user\/stocks\/blissgvs\/bliss-gvs-pharma-ltd-share-price-today?params=blissgvs&amp;params=bliss-gvs-pharma-ltd-share-price-today&amp;cacheClear=1781065641690\">Bliss GVS Pharma<\/a> share price target 2026<\/strong> is Rs 510, based on analyst estimates and the FY27 earnings recovery thesis for Bliss GVS Pharma (NSE: BLISSGVS). Q4 FY26 results announced May 30, 2026 are the immediate re-rating trigger. This article covers the complete <strong>Bliss GVS Pharma share price target<\/strong> analysis including sector tailwinds, peer context, key risks, and the bull and bear case scenarios updated May 30, 2026.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Bliss_GVS_Pharma_Share_Price_Target_2026_Key_Takeaways\" title=\"Bliss GVS Pharma Share Price Target 2026: Key Takeaways\">Bliss GVS Pharma Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Bliss_GVS_Pharma_Company_Overview\" title=\"Bliss GVS Pharma Company Overview\">Bliss GVS Pharma Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Why_Is_the_Bliss_GVS_Pharma_Share_Price_Target_Set_at_Rs_510_for_2026\" title=\"Why Is the Bliss GVS Pharma Share Price Target Set at Rs 510 for 2026\">Why Is the Bliss GVS Pharma Share Price Target Set at Rs 510 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#FY27_Earnings_Delivery_and_Revenue_Acceleration\" title=\"FY27 Earnings Delivery and Revenue Acceleration\">FY27 Earnings Delivery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Structural_Sector_Tailwinds_in_Pharmaceutical_Formulations_and_Export\" title=\"Structural Sector Tailwinds in Pharmaceutical Formulations and Export\">Structural Sector Tailwinds in Pharmaceutical Formulations and Export<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Union_Budget_2026-27_Policy_Support\" title=\"Union Budget 2026-27 Policy Support\">Union Budget 2026-27 Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Improving_FII_Flows_Post_the_April_2026_Tariff_Shock\" title=\"Improving FII Flows Post the April 2026 Tariff Shock\">Improving FII Flows Post the April 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Bliss_GVS_Pharma_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"Bliss GVS Pharma Share Price Targets: Short Term, 12 Month, and Long Term\">Bliss GVS Pharma Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Short_Term_Bliss_GVS_Pharma_Share_Price_Target_3_to_6_Months\" title=\"Short Term Bliss GVS Pharma Share Price Target: 3 to 6 Months\">Short Term Bliss GVS Pharma Share Price Target: 3 to 6 Months<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#12-Month_Bliss_GVS_Pharma_Share_Price_Target_2026\" title=\"12-Month Bliss GVS Pharma Share Price Target 2026\">12-Month Bliss GVS Pharma Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Long_Term_Bliss_GVS_Pharma_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Bliss GVS Pharma Share Price Target: FY27 to FY28\">Long Term Bliss GVS Pharma Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Bull_Case_and_Bear_Case_for_the_Bliss_GVS_Pharma_Share_Price_Target\" title=\"Bull Case and Bear Case for the Bliss GVS Pharma Share Price Target\">Bull Case and Bear Case for the Bliss GVS Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Bull_Case_Bliss_GVS_Pharma_Share_Price_Target_Rs_615\" title=\"Bull Case Bliss GVS Pharma Share Price Target: Rs 615\">Bull Case Bliss GVS Pharma Share Price Target: Rs 615<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Bear_Case_Bliss_GVS_Pharma_Share_Price_Target_Rs_340\" title=\"Bear Case Bliss GVS Pharma Share Price Target: Rs 340\">Bear Case Bliss GVS Pharma Share Price Target: Rs 340<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Key_Risks_to_the_Bliss_GVS_Pharma_Share_Price_Target_2026\" title=\"Key Risks to the Bliss GVS Pharma Share Price Target 2026\">Key Risks to the Bliss GVS Pharma Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#US_Tariff_and_Global_Macro_Risk\" title=\"US Tariff and Global Macro Risk\">US Tariff and Global Macro Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Valuation_and_Earnings_Miss_Risk\" title=\"Valuation and Earnings Miss Risk\">Valuation and Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Competitive_Pressure_in_Pharmaceutical_Formulations_and_Export\" title=\"Competitive Pressure in Pharmaceutical Formulations and Export\">Competitive Pressure in Pharmaceutical Formulations and Export<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#FII_Selling_Pressure_and_Liquidity_Risk\" title=\"FII Selling Pressure and Liquidity Risk\">FII Selling Pressure and Liquidity Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#How_to_Invest_in_Bliss_GVS_Pharma\" title=\"How to Invest in Bliss GVS Pharma\">How to Invest in Bliss GVS Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#FAQs_on_Bliss_GVS_Pharma_Share_Price_Target_2026\" title=\"FAQs on Bliss GVS Pharma Share Price Target 2026\">FAQs on Bliss GVS Pharma Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#What_is_the_Bliss_GVS_Pharma_share_price_target_for_2026\" title=\"What is the Bliss GVS Pharma share price target for 2026?\">What is the Bliss GVS Pharma share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#What_is_the_Bliss_GVS_Pharma_share_price_target_for_2025\" title=\"What is the Bliss GVS Pharma share price target for 2025?\">What is the Bliss GVS Pharma share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#Is_Bliss_GVS_Pharma_a_good_buy_at_Rs_42405\" title=\"Is Bliss GVS Pharma a good buy at Rs 424.05?\">Is Bliss GVS Pharma a good buy at Rs 424.05?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_Bliss_GVS_Pharma\" title=\"What is the 52 week high and low of Bliss GVS Pharma?\">What is the 52 week high and low of Bliss GVS Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#What_are_the_key_risks_to_the_Bliss_GVS_Pharma_share_price_target\" title=\"What are the key risks to the Bliss GVS Pharma share price target?\">What are the key risks to the Bliss GVS Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#What_are_the_catalysts_for_the_Bliss_GVS_Pharma_share_price_target\" title=\"What are the catalysts for the Bliss GVS Pharma share price target?\">What are the catalysts for the Bliss GVS Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#How_does_Bliss_GVS_Pharma_compare_to_its_peers\" title=\"How does Bliss GVS Pharma compare to its peers?\">How does Bliss GVS Pharma compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/bliss-gvs-pharma-share-price-target-2026\/#What_is_the_Bliss_GVS_Pharma_share_price_target_for_2027\" title=\"What is the Bliss GVS Pharma share price target for 2027?\">What is the Bliss GVS Pharma share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>Bliss GVS Pharma Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Bliss GVS Pharma share price target 2026:<\/strong> Rs 510 (base case, 20% upside from CMP Rs 424.05)<\/li>\n<li><strong>Bull case target:<\/strong> Rs 615 | <strong>Bear case target:<\/strong> Rs 340<\/li>\n<li><strong>NSE ticker:<\/strong> BLISSGVS | <strong>Sector:<\/strong> Pharmaceutical Formulations and Export | <strong>Market cap:<\/strong> Rs 2,544 crore<\/li>\n<li><strong>52 week range:<\/strong> Rs 283 to Rs 640 | <strong>Trailing PE:<\/strong> 18x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results (May 30, 2026) confirming FY27 earnings recovery<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or sustained FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Company_Overview\"><\/span><strong>Bliss GVS Pharma Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bliss GVS Pharma (NSE: BLISSGVS) is a Mumbai-based pharmaceutical company manufacturing and exporting specialised formulations including soft gel capsules, suppositories, and anti-malarial products to over 70 countries, with FY26 PAT growing 18 percent year-on-year. At CMP Rs 424.05 against a 52 week range of Rs 283 to Rs 640, the stock trades at a discount to its 52 week high. Market capitalisation stands at Rs 2,544 crore with a trailing PE of 18x. Compared to peers in specialty pharma export like Ipca Laboratories and Strides Pharma, Bliss GVS Pharma is positioned as a potential re-rating candidate toward the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510 on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>BLISSGVS<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceutical Formulations and Export<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 30, 2026)<\/td>\n<td>Rs 424.05<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 640<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 283<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 2,544 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>18x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 510<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 615<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 340<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction stock opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has now shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on current market momentum, sector trends &amp; growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">Top Stock Picks<\/a> now on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Bliss_GVS_Pharma_Share_Price_Target_Set_at_Rs_510_for_2026\"><\/span><strong>Why Is the Bliss GVS Pharma Share Price Target Set at Rs 510 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Delivery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Delivery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Bliss GVS Pharma share price target 2026<\/strong> of Rs 510 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results confirming the earnings recovery trajectory are the most direct catalyst for re-rating from CMP Rs 424.05 toward Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_Pharmaceutical_Formulations_and_Export\"><\/span><strong>Structural Sector Tailwinds in Pharmaceutical Formulations and Export<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Pharmaceutical Formulations and Export sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. Bliss GVS Pharma&#8217;s market position among peers in specialty pharma export like Ipca Laboratories and Strides Pharma creates a structural growth runway supporting the <strong>Bliss GVS Pharma share price target<\/strong> consensus of Rs 510 and the bull case of Rs 615.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle, which began in early 2026, reduces Bliss GVS Pharma&#8217;s borrowing costs and stimulates demand across end markets. Lower interest costs improve EPS trajectory, directly supporting the <strong>Bliss GVS Pharma share price target 2026<\/strong> of Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Policy_Support\"><\/span><strong>Union Budget 2026-27 Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Bliss GVS Pharma&#8217;s Pharmaceutical Formulations and Export operations, improving the probability of achieving the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Improving_FII_Flows_Post_the_April_2026_Tariff_Shock\"><\/span><strong>Improving FII Flows Post the April 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise post the April 2026 US tariff event, FII flows into quality Indian equities are recovering. At 18x PE, Bliss GVS Pharma is positioned as a beneficiary of institutional reallocation supporting the path to the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bliss_GVS_Pharma_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Bliss GVS Pharma Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Bliss_GVS_Pharma_Share_Price_Target_3_to_6_Months\"><\/span><strong>Short Term Bliss GVS Pharma Share Price Target: 3 to 6 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The near-term <strong>Bliss GVS Pharma share price target<\/strong> is anchored to support near the 52 week low of Rs 283. A confirmed Q4 FY26 earnings recovery serves as the trigger for an initial 10 to 15 percent re-rating toward the 12-month target of Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Bliss_GVS_Pharma_Share_Price_Target_2026\"><\/span><strong>12-Month Bliss GVS Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Bliss GVS Pharma share price target 2026<\/strong> is Rs 510, implying approximately 20 percent upside from CMP Rs 424.05. This base case assumes in-line FY27 earnings delivery and partial FII flow normalisation. Track live on NSE ticker BLISSGVS.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Bliss_GVS_Pharma_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Bliss GVS Pharma Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For investors with a 2 to 3 year horizon, the long-term <strong>Bliss GVS Pharma share price target<\/strong> is Rs 615 in the bull case, assuming full earnings delivery through FY27 to FY28 and sector re-rating among peers in specialty pharma export like Ipca Laboratories and Strides Pharma.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_the_Bliss_GVS_Pharma_Share_Price_Target\"><\/span><strong>Bull Case and Bear Case for the Bliss GVS Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Bliss_GVS_Pharma_Share_Price_Target_Rs_615\"><\/span><strong>Bull Case Bliss GVS Pharma Share Price Target: Rs 615<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case for the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 615 materialises when FY27 earnings beat estimates, sector tailwinds accelerate beyond consensus, and FII flows return strongly. The stock re-rates toward higher multiples, making Rs 615 achievable within FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Bliss_GVS_Pharma_Share_Price_Target_Rs_340\"><\/span><strong>Bear Case Bliss GVS Pharma Share Price Target: Rs 340<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case sees the <strong>Bliss GVS Pharma share price target<\/strong> testing Rs 340 if FY27 earnings disappoint and FII outflows persist. At Rs 340, the stock approaches the 52 week low of Rs 283, requiring a full reassessment of the investment thesis.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 615<\/td>\n<td>FY27 earnings beat, re-rating, strong FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>Rs 510<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 340<\/td>\n<td>FY27 earnings miss, guidance cut, FII outflows<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Bliss_GVS_Pharma_Share_Price_Target_2026\"><\/span><strong>Key Risks to the Bliss GVS Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"US_Tariff_and_Global_Macro_Risk\"><\/span><strong>US Tariff and Global Macro Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 26 percent US reciprocal tariff announced April 2, 2026 triggered FII outflows across Indian equities. Prolonged trade tension remains the most prominent macro risk to the <strong>Bliss GVS Pharma share price target 2026<\/strong> of Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Miss_Risk\"><\/span><strong>Valuation and Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any FY27 earnings miss or guidance cut could trigger multiple compression, posing a direct risk to the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510. Monitoring quarterly results closely is essential for investors tracking Bliss GVS Pharma.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Pressure_in_Pharmaceutical_Formulations_and_Export\"><\/span><strong>Competitive Pressure in Pharmaceutical Formulations and Export<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition among peers in specialty pharma export like Ipca Laboratories and Strides Pharma could compress Bliss GVS Pharma&#8217;s pricing power and market share over the medium term, which must be factored into any assessment of the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Selling_Pressure_and_Liquidity_Risk\"><\/span><strong>FII Selling Pressure and Liquidity Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay re-rating toward the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510 regardless of company-level improvement through FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Bliss_GVS_Pharma\"><\/span><strong>How to Invest in Bliss GVS Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Begin by reviewing Bliss GVS Pharma&#8217;s Q4 FY26 results, annual report, and FY27 guidance before forming a view on the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510. Focus on revenue growth trajectory, margin trends, and management commentary on Pharmaceutical Formulations and Export sector opportunities and headwinds.<\/p>\n<p>Open a Demat and trading account with a SEBI registered stockbroker to buy Bliss GVS Pharma (NSE: BLISSGVS) with full regulatory protection. Understand the competitive dynamics among peers in specialty pharma export like Ipca Laboratories and Strides Pharma before executing any position in Bliss GVS Pharma.<\/p>\n<p>Plan your entry near the 52 week low support of Rs 283. A confirmed Q4 FY26 earnings uptick and positive FY27 guidance would strengthen the entry case for the <strong>Bliss GVS Pharma share price target<\/strong> of Rs 510. Set a disciplined stop loss below the 52 week low.<\/p>\n<p>Restrict any single stock to 3 to 5 percent of your total equity portfolio to manage concentration risk, especially in the Pharmaceutical Formulations and Export space where sectoral cycles can amplify volatility beyond comfort levels.<\/p>\n<p>Always consult a SEBI registered financial advisor before investing based on any <strong>Bliss GVS Pharma share price target<\/strong> estimate. A registered advisor personalises recommendations based on your risk profile and financial goals. SEBI Registration No. INH000013776.<\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Bliss GVS Pharma&#8217;s live price and get daily stock recommendations.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Bliss_GVS_Pharma_Share_Price_Target_2026\"><\/span><strong>FAQs on Bliss GVS Pharma Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bliss_GVS_Pharma_share_price_target_for_2026\"><\/span><strong>What is the Bliss GVS Pharma share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Bliss GVS Pharma share price target 2026 is Rs 510, implying approximately 20 percent upside from the current market price of Rs 424.05. The bull case target is Rs 615 and the bear case is Rs 340, based on FY27 earnings estimates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bliss_GVS_Pharma_share_price_target_for_2025\"><\/span><strong>What is the Bliss GVS Pharma share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Bliss GVS Pharma share price target for 2025 was based on FY26 earnings expectations. The current 2026 analyst consensus target is Rs 510, reflecting FY27 growth projections and sector re-rating potential from CMP Rs 424.05.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Bliss_GVS_Pharma_a_good_buy_at_Rs_42405\"><\/span><strong>Is Bliss GVS Pharma a good buy at Rs 424.05?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 424.05, Bliss GVS Pharma offers potential upside to the share price target of Rs 510 if FY27 earnings recover as projected. Investment suitability depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Bliss_GVS_Pharma\"><\/span><strong>What is the 52 week high and low of Bliss GVS Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Bliss GVS Pharma is Rs 640 and the 52 week low is Rs 283. At CMP Rs 424.05, the stock trades at a discount to its 52 week high, creating upside potential toward the 12-month share price target of Rs 510.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Bliss_GVS_Pharma_share_price_target\"><\/span><strong>What are the key risks to the Bliss GVS Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Bliss GVS Pharma share price target of Rs 510 include an FY27 earnings miss, US tariff-driven FII outflows from Indian equities, competitive pressure in the Pharmaceutical Formulations and Export sector, and global demand slowdown. Monitoring quarterly results is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_catalysts_for_the_Bliss_GVS_Pharma_share_price_target\"><\/span><strong>What are the catalysts for the Bliss GVS Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Primary catalysts for the Bliss GVS Pharma share price target of Rs 510 include FY27 PAT recovery, structural tailwinds in Pharmaceutical Formulations and Export, RBI rate cut support reducing cost of capital, Union Budget 2026-27 policy uplift, and FII flow normalisation into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Bliss_GVS_Pharma_compare_to_its_peers\"><\/span><strong>How does Bliss GVS Pharma compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bliss GVS Pharma operates in the Pharmaceutical Formulations and Export sector alongside peers in specialty pharma export like Ipca Laboratories and Strides Pharma. At CMP Rs 424.05 with a market cap of Rs 2,544 crore, the company is positioned within its peer group as a potential re-rating candidate toward the share price target of Rs 510 on FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bliss_GVS_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Bliss GVS Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term Bliss GVS Pharma share price target for FY27 to FY28 is Rs 615 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows into Indian equities. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Bliss GVS Pharma share price target 2026 is Rs 510, ~20% upside from CMP Rs 424.05. Bull case Rs 615, bear case Rs 340. May 2026.<\/p>\n","protected":false},"author":28,"featured_media":111850,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3972],"class_list":["post-111107","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-share-price-target"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781065727:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_title":["Bliss GVS Pharma Share Price Target 2026: Rs 510 Analyst Forecast"],"rank_math_description":["The Bliss GVS Pharma share price target 2026 is Rs 510, ~20% upside from CMP Rs 424.05. Bull case Rs 615, bear case Rs 340. May 2026."],"rank_math_focus_keyword":["Bliss GVS Pharma Share Price Target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_wp_old_date":["2026-06-09"],"_thumbnail_id":["111850"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["16633"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Bliss-GVS-Pharma-Share-Price-Target.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/111107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=111107"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/111107\/revisions"}],"predecessor-version":[{"id":111851,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/111107\/revisions\/111851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/111850"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=111107"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=111107"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=111107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}